Factor IX Inhibitors and Anaphylaxis

Inhibitors in Patients with Haemophilia

Volumn , Issue , 2008, Pages 87-91

  Warrier, I ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Anaphylaxis; Factor ix inhibitors; Haemophilia b; Inhibitor development; Vitamin k dependent factors

Indexed keywords

EID: 84949453403     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470757260.ch14     Document Type: Chapter

References (21)

1. Warrier I, Ewenstein BM, Koerper MA et al Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997; 19: 23-7.
2. Warrier I, Lusher JM. Development of anaphylactic shock in hemophilia B patients with inhibitors. Blood Coag Fibrinolysis 1998; 9: 125-8.
3. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS Recombinant FVIII in previously untreated subjects with hemophilia A: a 3-5 year observational study of safety, efficacy and inhibitor development. N Engl J Med 1993; 328: 453-9.
4. Ehrenforth S, Kreuz W, Scharrer I et al. Incidence of development of factor VIII and factor IX in inhibitors in hemophiliacs. Lancet 1992; 339: 594-8.
5. Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort L, Hoyer L, Reisner H, Lusher JM White GC, eds. Inhibitors to Coagulation Factors. New York:Plenum Press, 1995: 35-45.
6. Briët E. Factor IX inhibitors in hemophilia B patients: their incidence and prospects for development with high purity factor IX products. Blood Coag Fibrinolysis 1991; 2 (Suppl.): 47-50.
7. High KA. Factor IX: molecular structure, epitopes and mutations associated with inhibitor formation. In: Aledort L, Hoyer L, Reisner HM, Lusher JM, White GC, eds. Inhibitors to Coagulation Factors. New York: Plenum Press, 1995: 79-86.
8. Katz J. Prevalance of FIX inhibitors among patients with hemophilia B: results of a large North American survey. Hemophilia 1996; 2: 28-31.
9. Warrier I Immune tolerance therapy in hemophilia B: possibilities and problems. Hemophilia Monitor 2000; 8: 3-6.
10. Ljung RC. Gene mutations and inhibitor formation in patients with hemophilia B. Acta Hematol 1995; 94 (Suppl. 1): 49-52.
11. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of hemophilias A and B. Blood Coag Fibrinolysis 1991; 2: 539.
12. Sawamoto Y, Midori S, Masakuni Y et al Measurement of antifactor IX subclass in hemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83: 279-86.
13. Dioun AF, Ewenstein BM, Geha RS et al. IgE-mediated allergy and sensitization to factor IX In hemophilia B. J Allergy Clin Immunol 1998; 102: 113-17.
14. Thorland EC, Drost JB, Lusher JM et al. Anaphylactic response to factor IX replacement therapy in hemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 1999; 5:101-5.
15. Warrier I Management of hemophilia B patients with inhibitors and anaphylaxis. Hemophilia 1998; 4: 574-6.
16. Nilsson IM, Berntorp E, Freiburghaus C. Treatment of patients with factor VIII and IX inhibitors. Thromb Hemost 1993; 70:56-9.
17. Ewenstein BM, Takemoto C, Warrier I et al Nephrotic syndrome as a complication of immune tolerance treatment in hemophilia B. Blood 1997; 89: 115-16.
18. Lenk H, Bierback U, Schille R. Inhibitor to FIX in hemophilia B and nephrotic syndrome in the course of immune tolerance treatment [Abstract]. Haemophilia 1996; 2 (Suppl.): 104.
19. Pollman H. A haemophilia B patient with complete FIX gene deletion and high titer antibody against FIX [Abstract]. Haemophilia 1996; 2 (Suppl.): 104.
20. Tengborn L, Hansson S, Fasth A et al Anaphylactoid reactions and nephrotic syndrome: a considerable risk during FIX treatment in patients with hemophilia B and inhibitorsaa report on the outcome of two brothers. Haemophilia 1998; 4: 854-9.
21. Perez R, Martinez ML, Sosa R. Nephrotic syndrome in A 12-yearold hemophilia B patient in the course of immune tolerance [Abstract]. Haemophilia 2000; 6: 311.